CJ Bioscience
Financials
Valuation Metrics
CJ Bioscience's Market Cap is ₩470B. At end of 2025 it was ₩1218B. Ranked #1778 of 2,436 in KR market (top 73%), #1079 of 1,649 on KOSDAQ (top 65%), #73 of 96 in Health Care Equipment & Services (top 76%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 47.04B KRW | KR#1,778/2,436 Sec#73/96 |
| Revenue | 3.56B KRW | KR#2,366/2,436 Sec#93/96 |
| Net Income | -23.00B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 65.09B KRW | KR#2,031/2,436 Sec#65/96 |
| Net Assets | 48.11B KRW | KR#1,903/2,436 Sec#61/96 |
| Employees | 129 | KR#1,436/2,436 Sec#50/96 |
| Value | ||
| P/B | 0.98x | KR#1,472/2,436 Sec#40/96 |
| P/S | 13.20x | KR#2,302/2,436 Sec#87/96 |
| FCF Yield | -49.81% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -47.81% | KR#2,261/2,436 Sec#85/96 |
| ROA | -35.34% | KR#2,328/2,436 Sec#91/96 |
| Op. Margin | -660.47% | KR#2,381/2,436 Sec#96/96 |
| Revenue Growth | -14.22% | KR#1,970/2,436 Sec#78/96 |
| Financial Health | ||
| Debt Ratio | 135.29% | KR#949/2,436 Sec#43/96 |
| Total Debt | 7.50B KRW | KR#1,707/2,436 Sec#56/96 |
| FCF | -23.43B KRW | KR#1,938/2,436 Sec#75/96 |
| Cash | 2.13B KRW | KR#2,236/2,436 Sec#92/96 |
| Current Ratio | 3.54x | KR#509/2,436 Sec#32/96 |
| Performance | ||
| 1Y Return | -62.69% | KR#2,274/2,436 Sec#89/96 |
| 1M Return | -22.50% | KR#2,263/2,436 Sec#89/96 |
| From 52W High | -65.48% | KR#1,975/2,436 Sec#69/96 |
| 1Y MDD | -69.35% | KR#1,925/2,436 Sec#69/96 |
| Trading | ||
| Volume | 7,155 shares | KR#2,202/2,436 Sec#91/96 |
| Foreign Own. | 2.73% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -1,761 KRW | KR—/2,436 Sec—/96 |
| BPS | 3,682 KRW | KR#1,672/2,436 Sec#43/96 |
Company Info
CJ Bioscience, a microbiome specialized company, was established in 2009 and listed on the KOSDAQ market in 2019. The company engages in therapeutic new drug development via its Artificial Intelligence-based microbiome big data platform, bioinformatics analysis services, and customized healthcare solutions. It offers new drug candidate material analysis based on the Ez-Mx® platform, microbial genome analysis utilizing EzBioCloud and N integrated solutions, and customized healthcare services leveraging a human microbiome database of over 140,000 cases. CJ Bioscience is headquartered in Jung-gu, Seoul.